These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37939825)

  • 1. Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study.
    Peng Z; Osmanaj F; Yang Y; Hua K; Yang X
    Europace; 2023 Nov; 25(11):. PubMed ID: 37939825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.
    Luo F; Sun L; Wang Z; Zhang Y; Li J; Chen Y; Dong J
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):91-98. PubMed ID: 35962156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the stand-alone Cox-Maze IV procedure to the concomitant Cox-Maze IV and mitral valve procedure for atrial fibrillation.
    Lawrance CP; Henn MC; Miller JR; Sinn LA; Schuessler RB; Damiano RJ
    Ann Cardiothorac Surg; 2014 Jan; 3(1):55-61. PubMed ID: 24516798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cox-Maze IV results for patients with lone atrial fibrillation versus concomitant mitral disease.
    Saint LL; Bailey MS; Prasad S; Guthrie TJ; Bell J; Moon MR; Lawton JS; Munfakh NA; Schuessler RB; Damiano RJ; Maniar HS
    Ann Thorac Surg; 2012 Mar; 93(3):789-94; discussion 794-5. PubMed ID: 22305055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial.
    Diederichsen SZ; Darkner S; Chen X; Johannessen A; Pehrson S; Hansen J; Svendsen JH
    Europace; 2019 Jul; 21(7):1055-1062. PubMed ID: 30843038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial).
    Darkner S; Chen X; Hansen J; Pehrson S; Johannessen A; Nielsen JB; Svendsen JH
    Eur Heart J; 2014 Dec; 35(47):3356-64. PubMed ID: 25182250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of the need for pacemaker implantation after the Cox maze IV procedure for atrial fibrillation.
    Masaki N; Kawamoto S; Motoyoshi N; Adachi O; Kumagai K; Kawatsu S; Hayatsu Y; Katahira S; Hosoyama K; Akiyama M; Saiki Y
    Surg Today; 2018 May; 48(5):495-501. PubMed ID: 29248960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dapagliflozin in improving arrhythmia-related outcomes after ablation for atrial fibrillation: a retrospective single-center study.
    Noh HJ; Cha SJ; Kim CH; Choi SW; Lee CH; Hwang JK
    Clin Res Cardiol; 2024 Jun; 113(6):924-932. PubMed ID: 38358416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus.
    Lee K; Lee SK; Lee J; Jeon BK; Kim TH; Yu HT; Lee JM; Park JK; Baek YS; Kim DH; Shim J; Joung B; Lee MH; Pak HN; Park J
    PLoS One; 2023; 18(1):e0280359. PubMed ID: 36652465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation.
    Kishima H; Mine T; Fukuhara E; Kitagaki R; Asakura M; Ishihara M
    JACC Clin Electrophysiol; 2022 Nov; 8(11):1393-1404. PubMed ID: 36424008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of the functional consequences of atrial fibrillation and surgical ablation on the left atrium using cardiac magnetic resonance imaging.
    Robertson JO; Lee AM; Voeller RK; Damiano MS; Schuessler RB; Damiano RJ
    Eur J Cardiothorac Surg; 2014 Oct; 46(4):720-8. PubMed ID: 24523494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early recurrence of atrial tachyarrhythmia during the 90-day blanking period after cryoballoon ablation in patients with atrial fibrillation: The characteristics and predictive value of early recurrence on long-term outcomes.
    Liu J; Yang H; Liu Y; Li X; Zhang H; Xia Y; Jia Y; Fang P; Tang M; Zhang S
    J Electrocardiol; 2020; 58():46-50. PubMed ID: 31715375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and risk of pacemaker implantation after the Cox-maze IV procedure.
    Robertson JO; Cuculich PS; Saint LL; Schuessler RB; Moon MR; Lawton J; Damiano RJ; Maniar HS
    Ann Thorac Surg; 2013 Jun; 95(6):2015-20; disussion 2020-1. PubMed ID: 23642681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental risk of the Cox-maze IV procedure for patients with atrial fibrillation undergoing mitral valve surgery.
    Saint LL; Damiano RJ; Cuculich PS; Guthrie TJ; Moon MR; Munfakh NA; Maniar HS
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1072-7. PubMed ID: 23998785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes.
    Abu-Qaoud MR; Kumar A; Tarun T; Abraham S; Ahmad J; Khadke S; Husami R; Kulbak G; Sahoo S; Januzzi JL; Neilan TG; Baron SJ; Martin D; Nohria A; Reynolds MR; Kosiborod M; Dani SS; Ganatra S
    JACC Clin Electrophysiol; 2023 Oct; 9(10):2109-2118. PubMed ID: 37565953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.